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Introduction
ptimizing the prevention and treatment of anxi-
ety disorders is a key goal for contemporary psychiatry,
given that these are the most common of the mental dis-
orders, that they increase the risk for comorbid mood and
substance use disorders, and that they contribute signifi-
cantly to the global burden of disease.
1,2 Pharmacotherapy
likely has the potential to make an important contribu-
tion to such interventions. 
Indeed, there have been a number of advances in the
pharmacotherapy of anxiety disorders in recent decades.
An important early step was the development of rigor-
ous clinical trial methods to quantify the efficacy and
safety of serendipitously discovered agents. A subse-
quent significant advance was the transition to more
focused pharmaceutical development of agents with
selective mechanisms of action. More recently, animal
laboratory studies and psychobiological clinical research
have further advanced our understanding of the neural
circuitry and molecular systems that underpin the anxi-
ety disorders, and so provided novel treatment targets.
Nevertheless, there remain significant challenges in the
field. These include various barriers to appropriate diag-
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Given the enormous contribution of anxiety disorders to
the burden of disease, it is key to optimize their preven-
tion and treatment. In this critical review we assess
advances in the pharmacotherapy of anxiety disorders, as
well as remaining challenges. In recent decades, the field
has seen rigorous clinical trial methods to quantify the
efficacy and safety of serendipitously discovered agents,
more focused development of medications with selective
mechanisms of action, and the gradual translation of
insights from laboratory research into proof-of-principle
clinical trials. On the positive side, a considerable database
of studies shows efficacy and relative tolerability of the
selective serotonin reuptake inhibitors in the major anxi-
ety disorders, and secondary analyses of such datasets
have informed questions such as optimal definition of
response and remission, optimal dose and duration, and
comparative efficacy of different agents. Significant chal-
lenges in the field include barriers to appropriate diag-
nosis and treatment of anxiety disorders, failure of a sig-
nificant proportion of patients to respond to first-line
pharmacotherapy agents, and a limited database of effi-
cacy or effectiveness studies to guide treatment in such
cases.    
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nificant proportion of patients to respond to first-line
pharmacotherapy agents, and an ongoing lack of data on
a number of key questions. In this paper we provide a
critical review of the pharmacotherapy of anxiety disor-
ders, summarizing advances in the field, as well as point-
ing out some of the areas that need to be addressed in
future work.
Generalized anxiety disorder
In many ways, developments in the pharmacotherapy of
generalized anxiety disorder (GAD) reflect the history
of the field of anxiety disorders as a whole. Anxiety is a
symptom that has been present since the beginning of
time, and anxiolytic agents have long been part of the
armamentarium of traditional healers and early physi-
cians. The effects of early medications were discovered
serendipitously, they sometimes had a poor risk:benefit
ratio (eg, the barbiturates), and trials were either nonex-
istent or limited by methodological problems including
a lack of reliable diagnostic criteria and valid measures
of symptom severity. 
The introduction of benzodiazepines and tricyclic anti-
depressants (TCAs) was an important advance in the
pharmacotherapy of GAD; these agents were studied in
rigorous randomized controlled trials, and were shown
to have an acceptable risk:benefit ratio.
3 Subsequent
work with agents that targeted particular molecular sys-
tems, such as the selective serotonin reuptake inhibitors
(SSRIs) and the serotonin and noradrenaline reuptake
inhibitors (SNRIs), constituted another important step,
insofar as the quality of trials and risk:benefit ratio fur-
ther improved.
4-7 (Table I). Indeed, most current treat-
ment guidelines emphasize that SSRIs and SNRIs are
the first-line pharmacotherapy agents of choice in
GAD.
8-11 Finally, more recent ongoing basic and clinical
psychobiology research has led to novel molecular tar-
gets for future development.
12-14
As their name suggests, SSRIs inhibit the reuptake of
serotonin at the presynaptic membrane by the serotonin
(5-HT) transport pump, thus increasing synaptic con-
centration of the neurotransmitter. SSRIs currently
available for clinical use are citalopram, escitalopram,
fluoxetine, fluvoxamine, paroxetine, and sertraline. There
is evidence to support the efficacy and tolerability of esc-
italopram, fluoxetine, paroxetine, and sertraline in the
short and longer-term management of GAD,
7,8 and both
escitalopram and paroxetine have FDA approval for this
indication.
15 Clinical trials have studied paroxetine 20 to
50 mg/day and escitalopram 10 to 20 mg/day,
5 but in
practice patients can be started on even low doses and
titrated up (for example an initial paroxetine dosage of
10 mg/day, titrated upwards every 7 days, may be used,
Table I).
16
TCAs inhibit reuptake of both noradrenaline and sero-
tonin, but also act on a range of other neurotransmitter
systems, accounting for their relatively poor safety and
tolerability profile. Venlafaxine and duloxetine are
SNRIs which act selectively to inhibit reuptake of nora-
drenaline and serotonin. The use of both agents in the
short-term management of GAD is supported by a num-
ber of RCTs,
6,7 and venlafaxine was the first antidepres-
sant to receive FDA approval for the treatment of
GAD.
16Venlafaxine studies used an initial dosage of 37.5
mg or 75 mg, which was then titrated up to a maximum
of 225 mg; duloxetine studies ranged from 60 to 120
mg.
17-19
There are relatively few maintenance studies of SSRIs
and SNRIs in the longer-term treatment of GAD.
7
However, such trials have consistently indicated that
early discontinuation of these agents is associated with
a high risk of relapse. Thus, most treatment guidelines
suggest that after a response to pharmacotherapy is
obtained, treatment should be continued for at least a
year, and that discontinuation should be done gradu-
ally.
3,9-11
Agomelatine is a melatonergic agonist (MT1 and MT2
receptors) and 5HT2C antagonist that is registered for
treatment of depression by the European Medical
Agency. There are also several lines of evidence sug-
gesting that agomelatine may be effective in GAD. First,
this agent demonstrates anxiolytic activity in various
rodent models.
20 Second, it reduces anxiety symptoms in
patients with depression.
21 Finally, agomelatine 25 to 50
mg/day was found efficacious in a recent trial in GAD.
22
Remarkably, agomelatine was as well tolerated as the
placebo, and patients suffered no discontinuation emer-
gent symptoms. Initial data from a relapse prevention
trial are also promising.
23
Benzodiazepines exert their anxiolytic effect by binding
to a specific site on the γ-aminobutyric acid (GABA)-
receptor, thus potentiating the effect of the inhibitory
neurotransmitter GABA. A number of randomized con-
trolled trials support the use of these agents in the short-
term treatment of GAD,
24 and alprazolam is FDA-
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15 A recent meta-
analysis found that the efficacy of benzodiazepines was
comparable to that of the SSRIs and venlafaxine in the
treatment of GAD.
25
However, although the benzodiazepines have the advan-
tage of a particularly early onset of action (sometimes
within 15 to 60 minutes), higher dosages of these agents
may be associated with a number of adverse effects,
including sedation, physical dependence, and impaired
concentration.
16 Furthermore, they are ineffective for
treating comorbid depression, and may be less effective
for treating the psychic than the somatic symptoms of
GAD.
26 Long-term use of these agents may be associated
with problematic withdrawal symptoms and rebound
anxiety.
16Thus most treatment guidelines do not recom-
mend benzodiazepines as a first-line pharmacotherapy
in GAD.
8-11
Buspirone is a partial agonist of the 5-HT1A receptor.
Although there is evidence of good efficacy and tolera-
bility in GAD,
27 clinicians remain somewhat sceptical of
its utility, perhaps because of relatively unfavorable
reports of its value from patients previously exposed to
benzodiazepines. Given the evidence base, buspirone
may certainly be considered in the treatment of patients
with GAD, and on theoretical grounds this agent may
have a particularly useful role in those with comorbid
alcohol dependence (where benzodiazepines are par-
tially contraindicated)
28 and in the augmentation of
SSRIs in treatment-refractory GAD.
29
Gabapentin and pregabalin are structurally analogous
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Study Year Population Intervention Effect of intervention
Paroxetine Rickels et al
158 2003 Adults (≥18 years) 8 weeks of paroxetine  Response was achieved by 62% and 68% of the 
20 or 40 mg/day,  patients receiving 20 and 40 mg of paroxetine,
or placebo. respectively, compared with a 46% response rate 
in the placebo group. Remission was achieved by 
30% and 36% of patients in the 20- and 40-mg 
paroxetine groups,respectively, compared with 
20% given placebo. Both doses of paroxetine 
were well tolerated.
Stocchi et al
159 2003 Adults Paroxetine (20-50 mg/ Significantly fewer paroxetine than placebo patients
day) for 8 weeks;  relapsed during the 24-week double-blind phase
followed by 24 weeks  (10.9% vs 39.9%; P<.001). Placebo patients were 
of paroxetine (n=278)  almost 5 times more likely to relapse than 
or placebo (n=288) paroxetine patients (estimated hazard ratio=0.213 
[95% CI=0.1 to 0.3]; P<.001). Twice as many 
paroxetine patients as placebo patients (73%) 
achieved remission. Paroxetine was well tolerated, 
with no unexpected adverse events reported.
Pollack et al
160 2001 Adults (≥18 years) Treatment with  A significantly greater proportions of paroxetine-
paroxetine (20-50 mg/ treated patients achieved response or remission by
day) or placebo for  week 8, compared with the placebo group.
8 weeks. Treatment with paroxetine was well tolerated.
Escitalopram Lenze et al
154 2009 Older adults  Twelve weeks of 10-20 mg/ Higher cumulative response rate for escitalopram
(≥60 years) day of escitalopram (n=85)  (69%; 95% CI 58%-80%) versus placebo
or matching placebo (51%; 95% CI 46%-67%)
Davidson et al
161 2004 Adults (≥18 years) Escitalopram 10 mg/day for  Response rates at week 8 were 68% for escitalopram
the first 4 weeks and then  and 41% for placebo (P<.01) for completers, and
flexibly dosed from 10-20  58% for escitalopram and 38% for placebo LOCF
mg/day (n=158), versus  values (P<.01).
placebo for 8 weeks
Table I. Selected placebo-controlled randomized controlled trials in generalized anxiety disorder.
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gated calcium channels in the CNS. They exert their
effects by increasing glutamic acid decarboxylase activ-
ity, thus also increasing levels of neuronal GABA and
inhibiting the release of excitatory neurotransmitters
such as glutamate, noradrenaline, and substance P.
30 A
number of randomized, placebo-controlled trials have
demonstrated efficacy and tolerability of pregabalin over
the short term, and pregabalin was effective in prevent-
ing symptom relapse.
30 Pregabalin was also found to be
efficacious and well-tolerated in elderly patients with
GAD.
31 The relatively favorable side-effect profile of
pregabalin makes it another useful treatment option in
GAD.
7 Current treatment guidelines recommend a dose
range of 150 to 600 mg/day for adult patients.
9
Antipsychotic agents have also been studied as
monotherapy in GAD. There is evidence that the atyp-
ical antipsychotic quetiapine is more effective than
placebo in improving clinical response and remission
rates in patients with GAD.
32,33 However, risk:benefit
ratio remains a concern given the possibility of adverse
events such as metabolic syndrome. On the other hand,
these agents may have a role to play in treatment-refrac-
tory patients, with evidence suggesting that various
antipsychotic agents may be beneficial as augmentation
strategies in those with treatment-refractory GAD.
34,35
Indeed, in clinical practice a significant proportion of
patients with GAD fail either to receive appropriate
therapy or to respond to first-line pharmacotherapy. An
immediate step in the management of the latter group
of patients is to ensure that diagnosis is correct, that psy-
chiatric and medical comorbidity has not been over-
looked, and that the trial is of sufficient duration and
dosage.
36 Next steps include switching to a different
agent, or augmentation.
8,9,16,37There are few switch stud-
ies in GAD, but the literature on depression suggests
that a different SSRI or an agent from a different class
might be useful in refractory cases. Pharmacotherapy
augmentation strategies include the addition to
SSRI/SNRI treatment of buspirone,
29 pregabalin,
38 or
low doses of atypical antipsychotics.
35,34Although data on
the value of combined pharmacotherapy and psy-
chotherapy in GAD is surprisingly limited,
39 psy-
chotherapy augmentation strategies may also be con-
sidered. 
In addition to the glaring absence of data on how best to
approach the treatment-refractory GAD patient, a num-
ber of other gaps in the literature deserve to be high-
lighted. First, most treatment data on GAD derive from
trials of GAD patients without comorbidity recruited by
academic centers; there are few data on effectiveness in
real-world settings, where the vast majority of patients
with GAD present, often with a range of comorbid psy-
chiatric and medical disorders and symptoms. Second,
there are relatively few data on “special” populations,
including children and adolescents and geriatric patients
with GAD,
40,41 or on whether early pharmacotherapy of
GAD is able to prevent subsequent onset of mood and
substance-use disorders.
42
Several promising future lines of investigation of GAD
have, however, been opened up by ongoing work on the
psychobiology of GAD. Work on the role of the gluta-
mate system in fear extinction,
43 on the role of neu-
ropeptides in stress responses,
44 and on a range of sec-
ond messenger or other downstream systems,
45,46 for
example, may ultimately lead to new treatments for
GAD. The development of a personalized approach to
the pharmacotherapy of GAD will depend ultimately on
the incorporation of genetic and/or imaging methodolo-
gies into research on the pharmacotherapy of GAD; sur-
prisingly little such work has been done to date, and
much more is therefore needed.
Obsessive-compulsive disorder
The serendipitous discovery that clomipramine (CMI),
a more serotonergic tricyclic, is effective for obsessive-
compulsive disorder (OCD) was important in giving
impetus to a serotonin hypothesis of OCD.
47 Subsequent
work found that the more selective SSRIs were not only
efficacious but also well-tolerated.
48 More recent psy-
chobiological research has focused on delineating the
role of neurotransmitters other than serotonin; dopamin-
ergic augmentation strategies have been used clinically
for some time now,
49 and a range of other molecular
treatment targets are being pursued.
50,51
Anecdotal reports of the efficacy of CMI in OCD were
followed by rigorous randomized controlled trials. Such
work demonstrated that clomipramine was more effica-
cious than both placebo and noradrenergic tricyclic
agents such as desipramine, and that it was efficacious in
both adults as well as in children and adolescents with
OCD.
52 Such work led to the first FDA approval for
OCD pharmacotherapy.
15 The use of intravenous (IV)
CMI for refractory OCD has also been investigated,
53,54
as this route of administration avoids first-pass hepatic
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form, desmethyl-clomipramine.
With the introduction of the SSRIs, several studies of
these agents were undertaken in OCD, and these gen-
erally showed efficacy and safety.
55 Fluoxetine, fluvox-
amine, paroxetine, and sertraline have all been FDA-
approved for OCD.
56 While several meta-analyses have
suggested that CMI may be more effective than SSRIs
(Table II),
57 this finding may reflect the fact that early
studies were characterized by a lower placebo response
rate. Head-to-head comparisons of CMI and SSRIs have
shown equal efficacy and superior tolerability for the
SSRIs.
58Thus, the SSRIs are now typically viewed as the
first-line choice for OCD.
8,9,11,56,59
A meta-analysis of medication dosage findings in OCD
suggests that patients who fail to respond to low-dose
therapy should be increased to a higher dose.
60 An ade-
quate trial in OCD should be at least 12 weeks in
length.
61 Although there is less published work on the
longer-term treatment of OCD, a number of studies
have demonstrated that early discontinuation often
leads to relapse.
58 Guidelines therefore suggest that
patients who respond to initial acute treatment should
then be continued for at least 1 year, and withdrawn
gradually.
8,9,56,59 It has been suggested that efficacy can be
maintained even after a reduction in dosage of long-
term treatment, with the benefits of improved tolerabil-
ity and adherence.
62
Unfortunately, up to 50% of patients with OCD treated
with an adequate trial of SSRI fail to respond fully.
63
Basic work on the psychobiology of OCD has suggested
that neurotransmitters other than serotonin may be
important in its pathogenesis. Indeed, the best studied
SSRI-augmenting agents in OCD are low-dose atypical
antipsychotics. Early work suggested that these were
particularly useful in patients with comorbid tics,
64 but
subsequent work has indicated that they may be useful
in both patients with and without tic disorders.
65,66
More recently, evidence for the role of the glutamater-
gic system in mediating OCD has emerged, and there
has been interest in using glutamate-modulating drugs
in the augmentation of treatment-resistant OCD. The
anticonvulsant agent topiramate, which inhibits gluta-
matergic neurotransmission, may be useful in treatment-
refractory OCD.
67 Riluzole, which inhibits the release of
glutamic acid, thus also blocking glutamatergic neuro-
transmission, has been found effective in proof of prin-
ciple trials.
68,69 Memantine, another glutamatergic agent,
may also be useful in treatment-refractory OCD.
70There
has also been interest in using the NMDA partial ago-
nist, cycloserine, in combination with CBT in OCD.
71
Several other somatic treatment options in OCD are also
being explored. First, a range of other mechanisms have
been targeted by SSRI-augmentation strategies, includ-
ing use of the 5-HT3 receptor antagonist, ondansetron.
72
Second, given the abundance of literature on autoimmu-
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Study Year Population Intervention Effect of intervention
Eddy et al
162 2004 Adult Psychotherapy and pharmacotherapy  A range of pharmacological and psychological 
interventions led to substantial improvement for the average 
patient, with individual psychotherapies, clomipramine, and 
other serotonin reuptake inhibitors faring best.
Ackerman and  2002 Adult CMI/SSRI (fluvoxamine, sertraline, CMI/SSRIs are superior to placebo in treating patients with
Greenland
163 paroxetine) vs placebo OCD.
Picinelli et al
164 1995 Adult Antidepressant drug treatment The response rate for CMI is superior to placebo and to SSRIs 
(fluoxetine, fluvoxamine, and sertraline).
Greist et al
165 1995 Adolescent-Adult  Serotonin transport inhibitors (STIs) Four STIs (clomipramine hydrochloride, fluoxetine
(aged 14+ yrs) hydrochloride, fluvoxamine maleate, and sertraline 
hydrochloride) are of substantial benefit for the treatment of 
OCD. An apparent efficacy advantage and low dropout rate 
was found for clomipramine. 
Stein et al
166 1995 Adult Serotonin reuptake inhibitors (SRIs) SRIs have a significant benefit, with clomipramine more 
effective than fluoxetine. 
Table II. Selected meta-analyses of obsessive-compulsive disorder treatment. CMI, clomipramine; SSRI, selective serotonin reuptake inhibitor; OCD,
obsessive-compulsive disorder
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of immunoglobulins and plasmapheresis in patients with
pediatric autoimmune neuropsychiatric disorders asso-
ciated with streptococcal infection (PANDAS).
73-75Third,
given the work on the neural circuitry of OCD, neuro-
surgery to remove specific lesions
76 or deep brain stimu-
lation after implantation of electrodes has been investi-
gated.
77,78 Such approaches provide promise for the future
management of refractory OCD.
Panic disorder
Research on the pharmacotherapy of panic disorder
(PD) was given significant impetus by the early
serendipitous finding that tricyclic antidepressants are
effective, and the hypothesis that different pharmaco-
logical agents are effective for different anxiety disor-
ders.
79 Subsequent research done in order to register
alprazolam and other benzodiazepines for the treatment
of panic disorder did not provide a great deal of support
for this hypothesis, but was important in contributing to
the development of clinical trial methods in this condi-
tion. Subsequent rigorous randomized controlled trials
of the SSRIs in PD were again an important advance
insofar as they provided an effective and relatively well-
tolerated treatment option.
80-82 As in the case of GAD
and OCD, however, much further work is required to
optimize the treatment of refractory cases. Fortunately,
ongoing studies of the psychobiology of PD have pro-
vided several leads which may be helpful in developing
more targeted therapies in the future.
80
Early work on tricyclic agents such as imipramine and
clomipramine demonstrated that these agents were effi-
cacious in PD, reducing the frequency of panic attacks
and the severity of anticipatory anxiety.
80 These older
agents appear as effective as more recent antidepressant
agents.
83 However, the widespread use of these agents is
limited by their relatively unfavorable side-effect pro-
file, including problematic anticholinergic and antia-
drenergic effects,
84 and they are not recommended as
first-line agents.
8-11
Similarly, while classic monoamine oxidase inhibitors
(MAOIs) may be effective for panic disorder, they are
not commonly prescribed for this indication. These
agents exert their antidepressant effect by inhibiting the
MAO enzyme, so decreasing the breakdown of sero-
tonin and noradrenaline and increasing the net level of
these neurotransmitters in the CNS.
15 However, as is the
case with TCAs, the widespread use of MAOIs is gener-
ally limited by their associated adverse effects (includ-
ing the risk of hypertensive crisis when taken with tyra-
mine-containing foods) and their numerous potential
drug interactions. 
Alprazolam, a short-acting agent, is the best studied ben-
zodiazepine in panic disorder.
80 It has shown efficacy com-
pared with placebo in short and longer-term studies, and
it has been found comparable in effect to the tricyclics and
to the SSRIs.
85Alprazolam as well as a number of other
benzodiazepines (clonazepam, diazepam, and lorazepam)
are FDA-approved for PD.
15 Nevertheless, once again,
given their relatively unfavorable side-effect profile, most
treatment guidelines do not list these agents as a first-line
option.
8-11
Fluoxetine, paroxetine, and sertraline have all been rig-
orously investigated in clinical trials and have received
FDA approval for use in PD.
15They are as effective, but
better tolerated, than the older TCAs.
83 There seems to
be little difference in efficacy within this group of
agents.
80 Current guidelines recommend that active med-
ication be continued for at least a year, in order to pre-
vent relapse and optimize outcome.
8-11
There is partial evidence that SNRIs and other newer
antidepressants are effective in PD.
80 On the one hand,
relatively few of these agents have been well studied in
PD, not all findings have been consistently positive, and
concerns have also been raised about the safety profile
of certain agents (eg, venlafaxine) in comparison with
the SSRIs.
85 On the other hand, there is some evidence
that more noradrenergic antidepressants may be of ben-
efit in PD patients who have failed to respond to sero-
tonergic antidepressants.
86 Thus SNRIs and some other
newer antidepressants (for example, mirtazapine and
reboxetine) can be considered as a treatment option in
the pharmacotherapy of PD.
87
There is also some evidence of the efficacy of other
classes of agent in panic disorder. In particular, anticon-
vulsant agents have been investigated for use. While
early RCTs found gabapentin and carbamazepine to be
of limited benefit compared with placebo,
88,89 valproate
may be effective in some patients.
90,91These medications
can perhaps be considered as augmenting agents in
treatment-refractory PD cases. However, more rigorous
clinical investigation is required before they can be rec-
ommended for widespread use.
80
Underdiagnosis and undertreatment of PD remains a
particular problem. Further, as above, a proportion of
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cotherapy. As always in such cases, diagnosis should be
reaffirmed, and duration and dose optimized.
8 Again,
while there has been relatively little rigorous work on
switching to agents of a different class, this is a reason-
able strategy.
37 Augmentation strategies that have been
researched include the addition of pindolol.
92,-94The addi-
tion of psychotherapy (CBT) to pharmacological treat-
ment may also be useful in PD.
95-100
As in the case of GAD and OCD, then, there has on the
one hand been significant progress in the pharma-
cotherapy of PD (including the introduction of the
SSRIs), while on the other hand several challenges
remain (including the treatment of patients refractory to
the SSRIs). Once again, psychobiological research has
provided tantalizing hints of novel treatment targets for
future work. Adenosine receptors may, for example, play
a unique role in the pathogenesis of PD, and may pro-
vide a novel target for future treatments of PD.
101
Alternatively, work on molecular systems that appear to
be involved in a number of different anxiety disorders
(eg, glutamate, the HPA axis), may also lead to new
treatments of PD.
12-14
Post-traumatic stress disorder
As has been the case in several anxiety disorders, early
trials for post-traumatic stress disorder (PTSD) focused
on agents that had been proven effective for depres-
sion,
102 namely TCAs and MAOIs. And once more, the
introduction of the SSRIs led to a series of multisite tri-
als showing comparable efficacy but better tolerability.
More recently, there has been ongoing work on the
treatment of refractory cases, using other classes of
agents such as atypical antipsychotics. Of particular
importance has been the emergence of proof-of-
principle trials, often grounded in animal literature.
These have focused on the pharmacotherapy of PTSD
prophylaxis and on the enhancement of psychotherapy
for this disorder. 
Several TCAs have been investigated in the treatment
of PTSD.
103-105Although some trials have shown efficacy,
the relatively unfavorable side effect profile of these
agents means that they are not considered a first-line
option in most treatment guidelines.
8,9,11,106-109 Similarly,
although MAOIs such as phenelzine may be effective in
PTSD,
110 their use remains limited by their safety and tol-
erability profile. 
A number of SSRIs and venlafaxine have been found to
be effective and safe in PTSD (Table III).
102 Paroxetine
and sertraline are FDA-approved for use in this disor-
der.
15 Most current guidelines therefore advocate the use
of one of the SSRIs and/or SNRIs as first-line pharma-
cotherapy.
8,9,11,106,108,109
The available literature suggests that a trial period of
about 8 to 12 weeks should be undertaken to assess effi-
cacy.
8,111 Long-term studies suggest that maintenance
treatment should be continued in responders for at least
a year.
102,112
Limited data exists on a number of other medication
classes in PTSD. For example, the anticonvulsants lam-
otrigine and topiramate have been found to be effective
as either monotherapy
113,114 or augmentation strategy.
115
Once again, however, given the relative paucity of data,
such agents are not considered a first-line option in the
pharmacotherapy of PTSD.
Limited work has been undertaken in patients not
responding to initial SSRI/SNRI treatment, or in special
populations such as children and adolescents.
41,116 In 
treatment-refractory patients, switching to a different
SSRI/SNRI can be considered, but has not been well stud-
ied. Augmentation with an atypical antipsychotic (eg.
risperidone or olanzapine) has been found efficacious in
some studies.
117-119 Other considerations include the addi-
tion of an anticonvulsant agent, for example topiramate.
115
Treatment guidelines emphasize the need for ongoing
assessment of the risk:benefit ratio of such strategies, for
example, monitoring metabolic effects.
8,106
Animal studies of stress have given impetus to the ques-
tion of whether PTSD can be prevented by early phar-
macotherapy. Early proof-of-principle studies suggested
that the β-blocker, propanolol, may be efficacious in this
context.
120,121The hypothalamic-pituitary-adrenal (HPA)
axis has been well-studied in both animal and human
work on stress, and the administration of IV hydrocorti-
sone in the hospital setting has been suggested useful in
PTSD prophylaxis.
122,123 However, subsequent work with
propanolol and other agents has not always been sup-
portive of the early work,
124,125 and further research in this
area remains necessary. 
Laboratory research also led to the hypothesis that D-
cycloserine, a partial agonist at NMDA (N-methyl D-
aspartate) glutamate receptors,
126 may be useful in
enhancing CBT in PTSD. Early proof-of-principle trials
have shown promise.
127,128 This is a particularly exciting
development, as it represents that, for perhaps the first
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led to an efficacious new treatment. Various other mol-
ecular targets for CBT augmentation have been sug-
gested,
12 but further work is needed to confirm the effec-
tiveness of such approaches in the clinical context. 
Social anxiety disorder
The pharmacotherapy of patients with social anxiety dis-
order (SAD) was given initial impetus by the finding
that MAOIs are effective, but TCAs are not. As in the
case of PD and OCD, this suggested that particular
agents might be efficacious for particular anxiety disor-
ders. And, once again, although the introduction of the
SSRIs for SAD did not support such the hope of phar-
macotherapeutic dissection, it did provide an effective
and well-tolerated pharmacotherapy. Again, despite the
availability of a range of medications for SAD, many
patients either do not respond or remit.
129 Thus, there is
an ongoing need for further work on treatment-refrac-
tory cases and novel treatment targets.
Early on the MAOIs showed efficacy for SAD in a num-
ber of placebo-controlled trials.
130 In particular,
phenelzine, an irreversible MAOI, was efficacious.
131-133
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Study year Population Intervention Effect of intervention
Paroxetine Marshall et al 2001
167 Adult outpatients Participants were randomly  Paroxetine-treated patients in both dose
assigned to take placebo, 20 mg/ groups demonstrated statistically significant
day of paroxetine, or 40 mg/day  response to treatment. Both doses of
of paroxetine for 12 weeks. paroxetine (20 and 40 mg/day) were well 
tolerated.
Tucker et al 2001
168 Adult outpatients  Participants were randomly At week 12, compared with the placebo
(≥18 years) assigned to treatment with  group, the paroxetine group showed
paroxetine (20-50 mg/day) or  significantly greater response to treatment
placebo for 12 weeks. and remission. Treatment with paroxetine
was well tolerated. 
Sertraline Brady et al 2000
169 Adult outpatients Patients were randomized to  Sertraline treatment yielded significantly
acute treatment with sertraline  greater response than placebo. Sertraline was
hydrochloride in flexible daily  well tolerated.
dosages of 50 to 200 mg/d, 
following 1 week at 25 mg/d; 
or placebo.
Davidson et al 2001
170 Adult outpatients Participants were randomized to  A 60% responder rate for sertraline and a
12 weeks of double-blind treatment  38% responder rate for placebo was found.
with either sertraline in flexible  Sertraline treatment was well tolerated.
daily doses in the range of 50 to 
200 mg or placebo.
Venlafaxine Davidson, Rothbaum  Adult outpatients Participants were randomly Week 12 remission rates were venlafaxine ER
et al 2006
171 assigned to receive placebo or  30.2%, sertraline 24.3%, and placebo 19.6%.
flexible doses of venlafaxine ER  The venlafaxine ER group had significantly
(37.5-300 mg/d) or sertraline  better scores on outcome measures than
(25-200 mg/d) for 12 weeks or less. placebo. Both treatments were well tolerated. 
Davidson, Baldwin  Adult outpatients Participants were randomly Improvement was significantly greater for the
et al 2006
172 assigned to receive flexible doses of  venlafaxine ER group, with a remission rate of
venlafaxine ER (37.5-300 mg/d) or  50.9%, compared with 37.5% for placebo.
placebo for 24 weeks. Withdrawal rates were similar between 
groups with no significant difference in 
dropouts attributable to adverse events. 
Table III. Selected placebo-controlled randomized controlled trials of post-traumatic stress disorder treatment.
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dietary restrictions and is associated with a range of
potential adverse events. 
The newer reversible MAOIs (RIMAs), such as
moclobemide and brofaromine, do not require such
dietary restrictions and are well tolerated. However, they
have not proved consistently efficacious in SAD
130,134; thus
although they are part of the current armamentarium,
they are not typically considered first-line agents.
8,9,11,135
The benzodiazepine clonazepam showed promise in the
short- and long-term treatment of patients with
SAD.
136,137 However, once again, given risk:benefit con-
siderations, benzodiazepines are not usually recom-
mended as first-line agents for SAD.
8,9,11,135
Several SSRIs have been shown to be efficacious and
relatively well-tolerated in the treatment of SAD.
138,130,139
Both paroxetine and sertraline are FDA-approved for
treatment of this disorder (Table IV). Given the sub-
stantial evidence base indicating the efficacy and safety
of SSRIs, they are typically recommended as the first-
line pharmacotherapy in treatment guidelines.
8,9,11,135
Of the SNRIs, venlafaxine is the best studied in SAD,
where it has shown efficacy in a number of RCTs.
134This
agent is therefore considered a reasonable alternative to
the use of SSRIs in a number of treatment guidelines,
and is FDA-approved for such use.
8,9,11,135
Current guidelines recommend that active treatment
with SSRIs/SNRIs should be continued for at least a
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Study Year Population Intervention Effect of intervention
Van der Linden  2000 Adult Pharmacological (SSRI)  The odds ratios of responder status for SSRI versus placebo varied between
et al
138 versus placebo 2.1 and 26.2. The number of patients who responded to drug treatment  
was approximately twice the number who responded to placebo. Response 
rates and effect sizes for SSRIs were larger than those seen in trials of the 
reversible monoamine oxidase inhibitors (RIMAs).
Federoff et al
173 2001 Adult Pharmacological  The most consistently effective treatments were pharmacotherapies.
(benzodiazepines, SSRIs,  Benzodiazepines and SSRIs were equally effective and more effective than
MOAIs); Placebo;  control interventions.
Psychological (exposure, 
cognitive restructuring, 
exposure plus cognitive 
restructuring, social skills 
training, and applied 
relaxation)
Blanco et al
174 2003 Adult Pharmacological The medications with largest effect sizes were phenelzine (effect size, 1.02; 
95% Confidence Interval [CI], 0.52–1.52), clonazepam (effect size,.97; 95% 
CI, 0.49–1.45), gabapentin (effect size,.78; 95% CI, 0.29–1.27), brofaromine 
(effect size,.66; 95% CI, 0.38–0.94), and the SSRIs (effect size,.65; 95% CI, 
0.50–0.81). There were no statistically significant differences between 
medications or medication groups. 
Stein et al
130 2004 Adult Pharmacological Response to treatment by SRIs (RR=0.67; 95% CI=0.59, 0.76), MAOIs 
(RR=0.43; 95% CI=0.24, 0.76) and RIMAs (RR=0.74; 95% CI=0.59, 0.91) 
supported the value of these agents. However, the SSRIs were significantly 
more effective than the RIMAs. Medication was also significantly superior to 
placebo. The value of long-term medication treatment in treatment 
responders was supported by 3 comparisons from maintenance studies 
(relative risk of non-response=0.58; 95% CI=0.39, 0.85) and 5 comparisons 
from relapse prevention studies (relative risk of relapse=0.33; 95% CI=0.22, 
0.49).
Hedges et al
175 2007 Adult Pharmacological (SSRIs) SSRIs are more effective than placebo for social anxiety disorder.
Table IV. Select meta-analyses in seasonal affective disorder treatment. SSRI, selective serotonin reuptake inhibitor, MAOI, monoamine oxidase inhibitor
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8,9,11This recommendation is supported by a number
of placebo-controlled relapse-prevention studies.
139
Several anticonvulsant agents have also been studied in
SAD.
134,140,141 Both gabapentin
88 and pregabalin, for exam-
ple, have shown efficacy compared with placebo.
However, neither agent is registered for the treatment
of SAD, and additional studies are required before their
routine use can be recommended.
A limited number of studies have investigated atypical
antipsychotics in SAD.
142A consideration of risk:benefit
ratio suggests that these agents should not yet be viewed
as a first-line option in SAD.
135 However, their role as an
augmenting strategy in treatment-refractory cases per-
haps deserves additional consideration.
Up to 50% of SAD patients do not respond to initial
pharmacological treatment.
129As always, diagnosis, dose,
and duration should be optimized.
36,135 Relatively small
switch studies have shown the benefit of treatment with
a different agent with proven efficacy, for example ven-
lafaxine
143 or phenelzine.
144Augmentation strategies that
may be considered include the use of buspirone,
145 clon-
azepam,
146 and combined pharmacological and psycho-
logical therapy.
133,147
There has again been interest in the possibility that D-
cycloserine may be useful in enhancing CBT. An early
proof-of-principle trial indicated that this agent was sig-
nificantly more effective than placebo in enhancing
CBT.
148 Other targets for CBT augmentation have also
been suggested,
12 and this seems an exciting area for
future investigation.
149As in the case of other anxiety dis-
orders, there is significant scope for studies that incor-
porate genetic and imaging methods into pharmacother-
apy studies,
150,151 aiming ultimately at individualizing
treatment approaches in SAD.
Conclusion
The glass of pharmacotherapy of anxiety disorders stud-
ies seems both half-full and half-empty. On the one hand,
there is a good number of randomized clinical trials of
anxiety disorders; these have been extensively reviewed
and meta-analyzed, and they include a particularly large
and persuasive set of studies showing efficacy and rela-
tively good tolerability of the SSRIs in the major anxiety
disorders. Secondary analyses of such datasets have
informed questions such as optimal definition of
response and remission, optimal dose and duration, and
comparative efficacy of different agents.
736,152 Innovative
questions, such as the use of pharmacotherapy for pro-
phylactic purposes, have begun to be studied.
42,108
On the other hand, a significant proportion of patients
with anxiety disorders fail to be diagnosed and treated,
1
or to respond to first-line agents, and there is a limited
database of efficacy or effectiveness studies to guide
treatment in such cases. Pharmacotherapy of children
and adolescents, and of the elderly with anxiety disor-
ders are other areas where some recommendations can
be made, but where much further work is needed.
153,154
There is a significant research gap in that most studies
have been undertaken at academic tertiary centers in
high-income countries for registration purposes, while
worldwide the vast majority of the clinical burden of
anxiety disorders manifests in low- and middle-income
countries in the community and in primary care.
Fortunately, although much remains to be learned about
the pathogenesis of the anxiety disorders, progress has
been made, and such work has led to some of the first
bedside neuroscience interventions ever to have
emerged directly from the bench.
127,155 Further such work
should be encouraged; there is significant scope for
merging new neuroscience methodologies, for example,
imaging and gene expression
156,157 with pharmacotherapy
studies in order to help find new treatment targets, and
in order to better personalize future treatment strategies.
Funding for such work may, however, require both pro-
fessionals and lay advocates to emphasize both the
untreated burden of anxiety disorders, as well as the rich
scientific opportunities that exist.  ❏
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Farmacoterapia de los trastornos ansiosos:
una revisión crítica
Considerando el gran impacto de los trastornos
ansiosos en el costo de las enfermedades, es clave
optimizar su prevención y tratamiento. En esta revi-
sión crítica se evalúan tanto los avances en la far-
macoterapia de los trastornos ansiosos como los
desafíos que persisten. En las últimas décadas en
este campo se ha contado con ensayos clínicos con
rigurosa metodología para cuantificar la eficacia y
seguridad de agentes descubiertos casualmente,
con el desarrollo más orientado a medicamentos
con mecanismos de acción selectiva y con el tras-
paso de ideas desde la investigación de laboratorio
a los ensayos clínicos de prueba de principios. Como
aspecto positivo debe considerarse que existe una
gran base de datos de estudios que demuestra la
eficacia y la aceptable tolerabilidad de los inhibi-
dores selectivos de la recaptura de serotonina en los
principales trastornos ansiosos, y del análisis secun-
dario de estas bases de datos han surgido pregun-
tas relacionadas con la definición óptima de res-
puesta y remisión, la dosis óptima y la duración y la
eficacia comparativa de diferentes fármacos. Existen
importantes desafíos en este campo que incluyen
las barreras para un apropiado diagnóstico y trata-
miento de los trastornos ansiosos, las fallas en la
respuesta a agentes farmacológicos de primera
línea de una proporción significativa de pacientes
y una base de datos limitada sobre la eficacia y
efectividad de estudios para guiar el tratamiento
en estos casos.  
Pharmacothérapie des troubles anxieux :
une revue critique
Du fait de l’importance de la contribution des
troubles anxieux au fardeau des maladies, il est cru-
cial d’optimiser leur prévention et leur traitement
Dans cette revue critique, nous évaluons à la fois les
avancées de la pharmacothérapie des troubles
anxieux et les défis qui persistent. Ces 10 dernières
années, des études cliniques rigoureuses ont permis
de quantifier l’efficacité et la tolérance de produits
découverts de manière empirique, de développer
plus précisément des médicaments aux mécanismes
d’action sélectifs et d’appliquer progressivement les
idées de la recherche en laboratoire à des études
cliniques basées sur des preuves. Du côté positif,
une importante base de données des études
montre une efficacité et une tolérabilité relative des
inhibiteurs sélectifs de la recapture de la sérotonine
dans les troubles majeurs de l’anxiété. Des analyses
secondaires de ces bases de données ont répondu
à des questions portant sur la définition optimale
de la réponse et de la rémission, de la meilleure
posologie, de la durée et de l’efficacité comparative
des différents produits. Les problèmes significatifs
qui persistent dans ce domaine sont : les obstacles
au diagnostic et au traitement adéquats des
troubles anxieux, l’absence de réponse d’un pour-
centage significatif de patients aux traitements de
première intention et une base de données limitée
pour les études d’efficacité pour orienter le traite-
ment dans de tels cas.
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